Pure Bioscience Alpha and Beta Analysis
| PUREDelisted Stock | USD 0.09 0.03 26.83% |
This module allows you to check different measures of market premium (i.e., alpha and beta) for all equities such as Pure Bioscience. It also helps investors analyze the systematic and unsystematic risks associated with investing in Pure Bioscience over a specified time horizon. Remember, high Pure Bioscience's alpha is almost always a sign of good performance; however, a high beta will depend on investors' risk tolerance level and may signal increased volatility and potential future overvaluation. Key technical indicators related to Pure Bioscience's market risk premium analysis include:
Beta (1.86) | Alpha 0.65 | Risk 0.0 | Sharpe Ratio 0.0 | Expected Return 0.0 |
Alpha is a measure of relative performance on a risk-adjusted basis, while beta measures volatility against the benchmark. The goal is to know if an investor is being compensated for the volatility risk taken. The return on investment might be better than its reference but still not compensate for the assumption of the risk.
Pure |
Pure Bioscience Market Premiums
Investors always prefer to have the highest possible return on investment, coupled with the lowest possible volatility. Pure Bioscience market risk premium is the additional return an investor will receive from holding Pure Bioscience long position in a well-diversified portfolio. The market premium is part of the Capital Asset Pricing Model (CAPM), which most analysts and investors use to calculate the acceptable rate of return on investment in Pure Bioscience. At the center of the CAPM is the concept of risk and reward, which is usually communicated by investors using alpha and beta measures. Alpha and beta are two of the key measurements used to evaluate Pure Bioscience's performance over market.| α | 0.65 | β | -1.86 |
Pure Bioscience Fundamentals Vs Peers
Comparing Pure Bioscience's fundamentals to the average values of its peers is one of the most widely used and accepted methods of equity analyses. It helps to analyze Pure Bioscience's direct or indirect competition across all of the common fundamentals between Pure Bioscience and the related equities. This way, we can detect undervalued stocks with similar characteristics as Pure Bioscience or determine the pink sheets which would be an excellent addition to an existing portfolio. Peer analysis of Pure Bioscience's fundamental indicators could also be used in its relative valuation, which is a method of valuing Pure Bioscience by comparing valuation metrics with those of similar companies.
| Better Than Average | Worse Than Average | Compare Pure Bioscience to competition |
| Fundamentals | Pure Bioscience | Peer Average |
| Return On Equity | -1.29 | -0.31 |
| Return On Asset | -0.62 | -0.14 |
| Profit Margin | (2.02) % | (1.27) % |
| Operating Margin | (1.98) % | (5.51) % |
| Current Valuation | 13.51 M | 16.62 B |
| Shares Outstanding | 111.36 M | 571.82 M |
| Shares Owned By Insiders | 41.23 % | 10.09 % |
Pure Bioscience Opportunities
Pure Bioscience Return and Market Media
The Stock did not receive any noticable media coverage during the period. Price Growth (%) |
| Timeline |
About Pure Bioscience Beta and Alpha
For many years both, Alpha and Beta indicators are used by professional money managers as critical performance measurement tools across virtually all financial instruments including Pure or other pink sheets. Alpha measures the amount that position in Pure Bioscience has returned in comparison to a selected market index or another relevant benchmark. In other words, Alpha is the excess return on an investment relative to the performance of your selected benchmark. Beta, on the other hand, measures the relative risk of your investment.
Pure Bioscience Upcoming Company Events
As portrayed in its financial statements, the presentation of Pure Bioscience's financial position is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Pure Bioscience's leadership is honest, while the outside auditors are strict and uncompromising. Whatever the case, investors should always follow all of Pure Bioscience's public filing events to personally review all filings and be reasonable and skeptical to interpret all of the financial statements of Pure Bioscience. Please utilize our Beneish M Score to check the likelihood of Pure Bioscience's management manipulating its earnings.
| 15th of March 2024 Upcoming Quarterly Report | View | |
| 31st of January 2024 Next Fiscal Quarter End | View |
Build Portfolio with Pure Bioscience
Your optimized portfolios are the building block of your wealth. We provide an intuitive interface to determine which securities in a portfolio should be removed or rebalanced to achieve better diversification, find the right mix of securities that minimizes portfolio risk for a given return, or maximize portfolio expected return for a given risk level.Build Diversified Portfolios
Align your risk with return expectations
Check out Your Equity Center to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area. You can also try the Headlines Timeline module to stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity.
Other Consideration for investing in Pure Pink Sheet
If you are still planning to invest in Pure Bioscience check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Pure Bioscience's history and understand the potential risks before investing.
| Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios | |
| Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
| Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals | |
| Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios |